These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32807645)

  • 21. Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?
    Uttley L; Tappenden P
    Curr Opin Pulm Med; 2014 Nov; 20(6):607-12. PubMed ID: 25221853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shifting patterns of inhaled antibiotic use in cystic fibrosis.
    Moskowitz SM; Silva SJ; Mayer-Hamblett N; Pasta DJ; Mink DR; Mabie JA; Konstan MW; Wagener JS;
    Pediatr Pulmonol; 2008 Sep; 43(9):874-81. PubMed ID: 18668689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colistin dry powder inhalation with the Twincer™: An effective and more patient friendly alternative to nebulization.
    Akkerman-Nijland AM; Grasmeijer F; Kerstjens HAM; Frijlink HW; van der Vaart H; Vonk JM; Hagedoorn P; Rottier BL; Koppelman GH; Akkerman OW
    PLoS One; 2020; 15(9):e0239658. PubMed ID: 32970760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2013 Oct; (10):CD005405. PubMed ID: 24170644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
    Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
    Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD005405. PubMed ID: 27412131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
    Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
    Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
    Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW
    Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.
    Collie D; Glendinning L; Govan J; Wright S; Thornton E; Tennant P; Doherty C; McLachlan G
    PLoS One; 2015; 10(11):e0142097. PubMed ID: 26544950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
    Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF).
    Frost F; Young GR; Wright L; Miah N; Smith DL; Winstanley C; Walshaw MJ; Fothergill JL; Nazareth D
    J Cyst Fibros; 2021 Nov; 20(6):994-1002. PubMed ID: 33358119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial.
    Puvvadi R; Mikkelsen H; McCahon L; Grogan S; Ditcham W; Reid DW; Lamont I; Stick SM; Clements B
    J Cyst Fibros; 2021 Mar; 20(2):316-323. PubMed ID: 33341406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
    Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
    Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR;
    Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.